Evidence map›Paper›PMID 40366166›Full record

ArticleJournal of clinical microbiology2025

Preliminary performance of the VIDAS TB-IGRA as an aid in the diagnosis of individuals infected with

Potiandi Serge Diagbouga, Arthur Diakourga Djibougou, Camille Pease, Ariana Alcaide, Audrey Berthoux, Natalie Bruiners, Daniela Maria Cirillo, Ardjouma Combary, Nadine Falchero, Deborah Handler and 16 more

Abstract readMulticenter StudyEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Diagnostic Performance of New Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis Infection: An Updated Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Potiandi Serge DiagbougaInstitut de Recherche en Sciences de la Santé, Centre National de la Recherche Scientifique et Technologique (IRSS/CNRST), Ouagadougou, Burkina Faso.ORCID 0000-0003-0920-1725
Arthur Diakourga DjibougouInstitut de Recherche en Sciences de la Santé, Centre National de la Recherche Scientifique et Technologique (IRSS/CNRST), Ouagadougou, Burkina Faso.ORCID 0000-0002-8077-6073
Camille PeaseDepartment of Research and Development for Immunoassays, bioMerieux, Marcy-l'Étoile, Auvergne-Rhône-Alpes, France.ORCID 0009-0009-9159-9955
Ariana AlcaideGlobal Tuberculosis Institute, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Audrey BerthouxDepartment of Research and Development for Immunoassays, bioMerieux, Marcy-l'Étoile, Auvergne-Rhône-Alpes, France.
Natalie BruinersPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Daniela Maria CirilloIRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID 0000-0001-6415-1535
Ardjouma CombaryProgramme national de lutte contre la tuberculose, Ouagadougou, Burkina Faso.
Nadine FalcheroDepartment of Research and Development for Immunoassays, bioMerieux, Marcy-l'Étoile, Auvergne-Rhône-Alpes, France.
Deborah HandlerGlobal Tuberculosis Institute, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Antoinette KaboréInstitut de Recherche en Sciences de la Santé, Centre National de la Recherche Scientifique et Technologique (IRSS/CNRST), Ouagadougou, Burkina Faso.ORCID 0000-0002-4187-4690
Alfred LardizabalGlobal Tuberculosis Institute, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Amanda LopesInternal Medicine Department, Département Médico-Universitaire INVICTUS, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Nord-Université Paris-Cité, Paris, France.
Marissa LoubetDepartment of Research and Development for Immunoassays, bioMerieux, Marcy-l'Étoile, Auvergne-Rhône-Alpes, France.
Philippe ManivetAPHP, Biobank Lariboisière BB-0033-00064, Platform of BioPathology and Innovative Technologies in Health, Hôpital Lariboisière, Paris, Île-de-France, France.
Clemence MargainDepartment of Research and Development for Immunoassays, bioMerieux, Marcy-l'Étoile, Auvergne-Rhône-Alpes, France.
Valerie MeunierDepartment of Research and Development for Immunoassays, bioMerieux, Marcy-l'Étoile, Auvergne-Rhône-Alpes, France.
Faiza MougariMycobacteriology Laboratory APHP-Nord associated to French National Reference Center for Mycobacteria, IAME, University Paris Cite, Paris, France.
Alberta OnyukaGlobal Tuberculosis Institute, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Sophie RivoironDepartment of Research and Development for Immunoassays, bioMerieux, Marcy-l'Étoile, Auvergne-Rhône-Alpes, France.
Tani SagnaInstitut de Recherche en Sciences de la Santé, Centre National de la Recherche Scientifique et Technologique (IRSS/CNRST), Ouagadougou, Burkina Faso.ORCID 0000-0002-8775-0693
Mathilde SanvertDepartment of Research and Development for Immunoassays, bioMerieux, Marcy-l'Étoile, Auvergne-Rhône-Alpes, France.
Léon SawadogoProgramme national de lutte contre la tuberculose, Ouagadougou, Burkina Faso.
Jacques SimporéCentre de recherche biomoléculaire Pietro Anigoni (CERBA), Ouagadougou, Burkina Faso.ORCID 0000-0002-0415-9161
Emmanuelle CambauMycobacteriology Laboratory APHP-Nord associated to French National Reference Center for Mycobacteria, IAME, University Paris Cite, Paris, France.ORCID 0000-0001-5944-2530
Maria Laura GennaroPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, New Jersey, USA.ORCID 0000-0003-4801-3567

Funding

Wellcome TrustWellcome Trust WT087535MA
6 · The paper itself

Abstract

This preliminary study compares VIDAS TB-IGRA (bioMérieux, Marcy-l'Etoile, France) with the established QuantiFERON-TB Gold Plus (QFT-Plus) (Qiagen, Hilden, Germany) to evaluate diagnostic performance for the diagnosis of individuals infected with

Indexed as

Interferon-gamma Release TestsLatent TuberculosisMycobacterium tuberculosisTuberculosisAdultAgedFemaleHumansMaleMiddle AgedSensitivity and SpecificityYoung AdultIGRAMycobacterium tuberculosis complexQFT-PlusVIDAS

Identifiers

PMID40366166
PMCPMC12153259

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.